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Prevalence of high-risk human papilloma virus
among women with hepatitis C virus before liver
transplantation
P.A. Tarallo, J. Smolowitz, D. Carriero, J. Tarallo, A. Siegel, H. Jia,
J.C. Emond. Prevalence of high-risk human papilloma virus among
women with hepatitis C virus before liver transplantation.
Transpl Infect Dis 2013: 15: 400–404. All rights reserved
Abstract: Background. We sought to assess the prevalence and
risk factors for high-risk human papillomavirus (HPV) infection
among female liver transplant (LT) candidates. Traditional health
screening before LT listing has included Pap smear and is typically
carried out by the patient’s local provider. The prevalence of highrisk HPV in this population has not been studied.
Methods. With Institutional Review Board approval, 62 LT
candidates received a liquid-based Pap smear with high-risk HPV
testing as part of their pre-transplant evaluation by a single provider.
Clinical variables included age, ethnicity, insurance status, prior Pap
smear, and HPV results, HPV risk factors including age of first
intercourse, number of lifetime partners, last sexual activity,
smoking, birth control pill use, history of sexually transmitted
infections, human immunodeficiency virus status,
immunosuppressive medication, medical diagnoses, prescribed
medications, and history of hepatitis A, B, C, or D.
Results. The 62 women had a median age of 56 years, and 39% had
high-risk behavior known to be associated with HPV. Ten of 62
patients (16.1%) had high-risk HPV at baseline screening, 5 of whom
had atypical cytology. All of the patients who were positive for highrisk HPV had an etiology of hepatitis C virus (HCV) as the
underlying cause of liver disease, with the majority (90%) having no
history of high-risk behavior for HPV. In contrast, all patients with
high-risk behavior who were HCV negative were HPV negative.
Fisher’s exact test demonstrated a statistically significant
relationship between HPV and HCV; odds ratio = 24.4,
95% confidence interval 1.4, 438.7, P-value = 0.0013. None of the
other potential risk factors were associated with HPV in this cohort.
Conclusions. In this study, we provide evidence of a strong
association between HCV and HPV in LT candidates, which has not
been previously reported. HPV positivity was observed in nonsexually active women, suggesting a reactivation of dormant HPV.
An association between hepatitis C and high-risk HPV could involve
impairment of T-cell function by hepatitis C. These data support
close surveillance in women’s health screening for LT candidates.
Further studies to characterize immune responses in these patients
will be in order.

Human papillomavirus (HPV) is detected in >90% of
cervical cancers. A causal relationship between HPV
and lower genital tract neoplasms has been established.
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In 2010, there were 12,200 estimated new cases of
cervical cancer in the United States and 4210 estimated
deaths (1, 2). Annual incidence of newly diagnosed
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HPV is an estimated 6.2 million cases worldwide, with
approximately 500,000 new cases of cervical cancer and
274,000 related deaths.
Oncogenic or high-risk HPV infection has been
identified as an underlying cause of cervical cancer
(3) and the World Health Organization has designated
HPV infection as necessary for cervical cancer development (4). High-risk HPV types include 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 (5).
Persistent infection with oncogenic or high-risk types of
HPV is strongly associated with the development of
cervical cancer (6).
The immune system plays a major role in persistence
of HPV infections, and the oncogenic potential of HPV
may be enhanced by immunosuppression (7). Immunocompetent women infected with HPV usually eradicate
virus within 24 months, regardless of viral oncogenicity
(8). Reactivation of latent DNA viruses, such as EpsteinBarr virus, cytomegalovirus, herpes simplex, and hepatitis B, and of RNA viruses, such as hepatitis C virus
(HCV) and human T-lymphotropic virus 1, has been
documented in immunocompromised hosts and organ
transplant recipients (9). Similarly, HPV reactivation can
occur and lead to malignancies without proper surveillance in long-term transplant survivors.
Organ transplant recipients have a high risk of
developing other malignancies, because of lifelong
immunosuppressive therapy. These patients are susceptible to cancers that have been linked to viral
infections, such as non-Hodgkin lymphoma and Hodgkin lymphoma (to Epstein–Barr virus), Kaposi sarcoma
(to human herpesvirus-8), adult T-cell leukemia (to
human T-lymphotropic virus 1) (10), hepatocellular
carcinoma (to hepatitis B virus and HCV), and anogenital cancers, which include cervical, vaginal, perianal, and vulvar malignancies (to HPV) (11).
We conducted a retrospective chart review of 266 female
liver transplant (LT) recipients, ages 18–70 years, followed
in our center. Sixteen patients (6%) were documented to
have had a pre-transplant Pap smear, and of these only 1
was tested for HPV. To address this deficiency in clinical
practice, a protocol was introduced that offers gynecology
exam and HPV screening to women, ages 18–70, referred
for transplant evaluation. All women with abnormal Pap
smears and/or positive HPV test receive follow-up care
according to the American Society for Colposcopy and
Cervical Pathology treatment guidelines.

Patients and methods
Institutional Review Board approval was obtained
before study enrollment. Women with history of liver

transplantation were excluded from the study, as they
were already on immunosuppressive medication. All
women referred for LT evaluation were asked to
participate and provide informed consent.
Study subjects received a baseline Pap smear, HPV
screening, and education about cervical cancer
screening as part of their pre-transplant evaluation.
Demographic and clinical information obtained at
the time of the initial visit included HPV risk
factors, age of first sexual encounter, number of
lifetime partners, most recent sexual activity, tobacco
history, oral contraception use, detailed history of
sexually transmitted infections, human immunodeficiency virus (HIV) status, medical diagnoses,
etiology of underlying liver disease, and all prescribed medications, including immunosuppressive
agents.
Descriptive data were summarized with means,
medians, standard deviations, frequency, and percentages. Fisher’s exact test was used to determine the
statistical significance of the relationship between HPV
and etiology of liver disease. Statistical analyses were
conducted using SPSS version 13 (SSPS Inc., Chicago,
Illinois, USA).

Results
In total, 62 women were screened for cervical/vaginal
high-risk HPV before liver transplantation. Median age
was 56 years (27–69). Hispanics represented 54.9% of
the cohort. HCV was the underlying cause of liver
disease in 54.8% of subjects. Other causes of liver
disease are summarized in Table 1.
Over half of the group (53.8%) reported no history of
smoking, 6 subjects (9.6%) reported a history of
injection drug use, and a third of the cohort (32.7%)
reported a history of >1 alcoholic drink per day. Three
women had HIV infection, and another 7 subjects
(11.6%) reported history of other sexually transmitted
infections. Twenty-five percent of subjects reported
 5 sexual partners in their lifetime. Current sexual
activity versus abstinence of 10 years or longer was
reported among 38.5% and 61.5% of women, respectively.
Fifty-eight subjects (93.5%) had normal Pap cytology
while 5 women (6.5%) had atypical squamous cells of
undetermined significance. HPV screening identified
10 subjects (16.1%), ages 46–61 years, with high-risk
HPV. All women with high-risk HPV had chronic HCV
(Table 2), and 90% of these reported no risk factors for
HPV (P = 0.0013) (Table 3).
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Population characteristics (N = 62)
Variable

Risk factors for woman with human papilomavirus (HPV) infection

Number

Percentage

Age, years (Mean = 54,
Median = 56)

Variables

HPV+ (n = 10)

HPV

(n = 52)

Smoking

27–37

6

9.7

38–48

6

9.7

49–59

28

45.2

60–69

22

35.4

HCV

34

54.8

AIH

10

16.1

NASH

4

6.5

ETOH

3

4.8

Other

11

17.8

34

54.9

Caucasian

17

27.4

Black

9

14.5

Asian

2

3.2

Never

7 (70%)

28 (53.8%)

Quit >10 y

2 (20%)

14 (27%)

Quit <10 y

1 (10%)

10 (19.2%)
0.42

<5 lifetime

9 (90%)

39 (75%)

>5 lifetime

1 (10%)

13 (25%)

Never

9 (90%)

47 (90.4%)

History

1 (10%)

5 (9.6%)

IVDA

1.00

ETOH abuse

Ethnicity
Hispanic

0.62

Sexual partners

Etiology of liver disease

0.26

No history

9 (90%)

35 (67.3%)

History

1 (10%)

17 (32.7%)

Sexual activity

0.73

>10 y

7 (70%)

32 (61.5%)

Currently active

3 (10%)

20 (38.5%)

No history

9 (90%)

46 (88.4%)

History

1 (10%)

6 (11.6%)

STI

HCV, hepatitis C virus; AIH, autoimmune hepatitis; NASH, nonalcoholic steatohepatitis; ETOH, ethanol.

1.00

HIV

Table 1

Association of females with human papilloma virus (HPV) and hepatitis
C virus (HCV)
HPV+

HPV

Total

HCV+

10

24

34

HCV

0

28

28

Total

10

52

62

P-value

0.51

Negative

9 (90%)

49 (94.2%)

Positive

1 (10%)

3 (5.8%)

y, years ago; IVDA, intravenous drug abuse, ETOH, ethanol; STI,
sexually transmitted infection; HIV, human immunodeficiency virus.

Table 3

OR = 24.4, 95% CI of OR is (1.4, 438.7); P-value = 0.0013 (based
on Fisher’s exact test).
OR, odds ratio; CI, confidence interval.

Table 2

Discussion
Limited research is available on HPV incidence or
prevalence in liver transplantation patients before and
after transplant. In this cohort of 62 pre-transplant
female subjects, 10 had high-risk HPV at baseline
screening and 5 had atypical cytology. All of the
patients who were positive for high-risk HPV had an
etiology of HCV as the underlying cause of liver
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disease, and 90% reported no identifiable risk factors
for HPV.
There is compelling evidence of HPV-related infections and malignancies among renal transplant recipients and the HIV+ population. Serraino et al. (12)
examined the risk of cancer following immunosuppression in solid organ transplant recipients and in HIV+
individuals in Southern Europe. The transplant group
consisted of 1829 kidney transplants, 682 heart transplants, 42 lung transplants, and 322 LTs. After 5 years,
3.1% in the HIV+ group and 4.4% of transplant recipients
had developed cancer. The cumulative probabilities of
cancer at 15 years in the HIV and transplant cohorts,
were 13.3% and 14.7%, respectively (12).
A meta-analysis of cancer incidence among patients
with HIV/AIDS and immunosuppressed transplant
recipients found a substantially higher rate of HPVrelated cancers in the transplant group. However,
infection-related cancers, such as those related to
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HPV, were more prevalent in immunosuppressed
patients, independent of the source of immune deficiency (13).
Roka et al. (14) conducted a clinical trial to determine
the prevalence of anal HPV in solid organ transplant
patients. The study included 43 kidney and 17 LT
patients. A 10-fold increased relative risk for the
development of anal cancer in transplanted patients,
and a strong association between persistent high-risk
HPV with ano-genital neoplasia, including cervical, anal,
vulvar, penile, and vaginal cancers, have been reported
in the literature. HPV was detected in 23% (14/60) of
patients, with 15% having high-risk HPV, 13.4% having
low-risk HPV, and 5% having both types. The prevalence of HPV was higher in LT than in kidney
transplant patients (29.4% vs. 20.9%), although this
was not statistically significant. HPV infection was
found in 23% of patients before immunosuppression.
Although this study provided needed information about
this population, it is unclear whether the outcomes
were different because of the type of organ being
transplanted or the regimen (14).
Data from our study of pre-transplant subjects demonstrate several important findings. Hispanics represented 54.9% of the cohort, with a median age of 56.
Datta et al. (15) looked at high-risk HPV prevalence by
demographic characteristics, and Hispanics had 20%
prevalence of high-risk HPV, non-Hispanics 24%, and
unknown ethnicity revealed 21%, with only 6% within
the ages of 50–65. Baseline general population prevalence data for HPV infection in the United States
revealed that women aged 20–24 years had the highest
prevalence of HPV at 44.8%, with a steady decline with
age (16).
Sixteen percent of patients were found to have highrisk HPV infection before transplantation. All high-risk
HPV-positive patients had HCV as the underlying cause
of their liver disease. Ninety percent of these patients
had no known risk factor for HPV. Although the sample
size is small, it is intriguing that patients with high-risk
HPV reported no history of recent sexual activity or
identifiable risk factors for HPV, and had concomitant
HCV infection. The absence of sexual activity for
>5 years excludes the possibility of new infection.
We know that HPV can become a persistent chronic
infection through an efficient immune evasion mechanism. Because HPV infects and replicates in keratinocytes, which are distant from immune centers and have
a short life span, it evades the innate immune response
and delays the activation of the adaptive immune
response. In addition, like most DNA viruses, HPV
has evolved mechanisms to inhibit antiviral interferon
(IFN) synthesis and signaling. High-risk HPVs down-

regulate IFN-a-inducible gene expression, and HPV
oncoproteins interfere with IFN signaling (17).
However, almost all natural history studies show that
genital HPV infection is common in young sexually
active women, and most infections “clear” effectively.
Failure of the immune response to clear or control the
infection results in viral persistence. Individuals with
impaired immunity have increased probability of progression to high-grade cervical intraepithelial neoplasia
(CIN 2/3) and invasive carcinoma. This vulnerability is
evidenced by the increased incidence and progression
of HPV infections in HIV+ patients (18).
Cirrhosis has been characterized as the most common acquired immunodeficiency syndrome worldwide
(19). It is associated with several immune system
abnormalities, specifically, decreased monocyte function, characterized by a deficiency in adherence and
phagocytosis, altered natural killer activity, and lectininduced proliferation of T lymphocytes.
Finally, an increased concentration of serum immunoglobulin in patients with liver cirrhosis may indicate
an altered balance between T-lymphocyte helper (Th)
responses implicated in cytotoxicity (Th1) and those
implicated in the synthesis of specific antibodies (Th2)
(20). Therefore, we hypothesize that the immunodeficiency associated with HCV cirrhosis may contribute to
persistence of infection and increase the risk for
incident high-grade intraepithelial lesions in this group
of women with high-risk HPV infection.
These findings have important practice implications
with regard to preventive care for this population.
Cervical cancer screening guidelines in the general
population have recently been revised and recommend
screening for women beginning at age 21 regardless of
the age sexual activity was initiated. These guidelines
do not address special populations who may need more
intensive or alternative screening. These include
women (i) with a history of cervical cancer, (ii) who
were exposed in utero to diethylstilbestrol (DES), and
(iii) who are immunocompromised (e.g., infection with
HIV) (21). Women who are immunocompromised from
end-stage liver disease should be included in this
category. The time interval has not yet been established for screening women who are immunocompromised.
Renal transplant is the most frequently performed
organ transplant. Although minimal data are available
regarding cervical screening in liver disease, there are
recommendations for renal transplantation recipients.
The American Society of Transplantation and the
European Best Practice guidelines advise annual cervical screening and pelvic exam in women who are renal
transplant recipients (22).
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It is acceptable to follow general population guidelines and not begin screening before age 21. The
majority of adult patients who require liver transplantation are over the age of 30 (23). However, it is
reasonable to apply renal transplant guidelines to
women who are immunocompromised secondary to
liver disease. Immunosuppression is one of the most
significant risk factors for the development of highgrade ano-genital lesions and cervical cancer. These
persons are at risk for persistent and multiple types of
HPV infections (24).
Further data are needed to describe the population,
risk factors, and prevalence of high-risk HPV among
women enrolled in transplantation programs. Controlled prospective studies should be conducted to
determine risks for development of cervical cancer in
this population. As liver transplantation becomes more
successful and patients live longer, clinicians must
understand the risks of secondary cancer development
and the need for early detection and prevention by
improving surveillance before and after transplant.
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